Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
96.5M
-
Number of holders
-
169
-
Total 13F shares, excl. options
-
77M
-
Shares change
-
-1.91M
-
Total reported value, excl. options
-
$605M
-
Value change
-
-$36M
-
Put/Call ratio
-
1.85
-
Number of buys
-
98
-
Number of sells
-
-69
-
Price
-
$7.83
Significant Holders of AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) as of Q1 2025
217 filings reported holding AVDL - AVADEL PHARMACEUTICALS PLC - Common Stock as of Q1 2025.
AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) has 169 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 77M shares
of 96.5M outstanding shares and own 79.82% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (13.6M shares), GENDELL JEFFREY L (6.13M shares), BRANDES INVESTMENT PARTNERS, LP (5.67M shares), BlackRock, Inc. (5.45M shares), Two Seas Capital LP (4.95M shares), Polar Capital Holdings Plc (4.36M shares), VANGUARD GROUP INC (3.9M shares), Vivo Capital, LLC (2.68M shares), WEALTH EFFECTS LLC (2.37M shares), and CITADEL ADVISORS LLC (2.25M shares).
This table shows the top 169 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.